Plaintiffs argue that the manufacturers knew or should have known about these risks based on clinical data, adverse event reports, medical literature, and post-market safety information
0.2 years in diabetic patients with cardiovascular risk factors only, suggesting an additional benefit of semaglutide in this population with high cardiovascular risk.88 The mechanisms involved in the cardiovascular benefits of this family are various
Think of two people on the same GLP-1 medication: Person A: eats less by default, but doesnt prioritize protein, micronutrients, sleep, or resistance training
Clinical studies indicate that stopping GLP-1 therapy abruptly can lead to weight regain due to hormonal and metabolic adaptations
The findings dont necessarily suggest taking a GLP-1 will keep you from developing Alzheimers disease one day, but researchers did uncover some interesting elements that suggest these drugs may help, in certain groups, at least